Lead Product(s) : ACT-709478
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Neurocrine Biosciences
Deal Size : $410.0 million
Deal Type : Licensing Agreement
Details : Neurocrine Biosciences to develop and commercialize ACT-709478, a clinical stage selective T-type calcium channel blocker for the treatment of a rare pediatric epilepsy.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $45.0 million
November 05, 2020
Lead Product(s) : ACT-709478
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Neurocrine Biosciences
Deal Size : $410.0 million
Deal Type : Licensing Agreement
Lead Product(s) : ACT-709478
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Neurocrine Biosciences
Deal Size : $417.0 million
Deal Type : Licensing Agreement
Details : Under this agreement, Neurocrine Biosciences owns option to exclusively license ACT-709478, a clinical stage selective T-type calcium channel blocker for the treatment of epilepsy.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $45.0 million
October 01, 2020
Lead Product(s) : ACT-709478
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Neurocrine Biosciences
Deal Size : $417.0 million
Deal Type : Licensing Agreement
Lead Product(s) : ACT-709478
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Compare a Single-dose of Two Different Formulations of ACT-709478 in Healthy Men
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2019
Lead Product(s) : ACT-709478
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ACT-709478
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2017
Lead Product(s) : ACT-709478
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ACT-709478
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate Safety and Tolerability of ACT-709478 in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2017
Lead Product(s) : ACT-709478
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
